| 12145917 |
Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
Shunqi Yan, Litain YEH, Ruiping Wang |
2024-11-19 |
| 11236081 |
Crystalline salts of corydalmine |
Zheng-Yu Yang, Zhicong Shi |
2022-02-01 |
| 9981961 |
Deoxycytidine kinase inhibitors |
Caius G. Radu, Raymond M. Gipson, Jue Wang, Nagichettiar Satyamurthy, Arnon Lavie +3 more |
2018-05-29 |
| 9598404 |
Deoxycytidine kinase inhibitors |
Caius G. Radu, Raymond M. Gipson, Jue Wang, Nagichettiar Satyamurthy, Arnon Lavie +3 more |
2017-03-21 |
| 7960407 |
Crystal forms of an imidazole derivative |
Naoaki Haruta, Tomoki Kato, Toyoharu Numata, Andrew Trask |
2011-06-14 |
| 7803805 |
Cristalline 3-{(3R,4R)-4 methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt |
Mark E. Flanagan |
2010-09-28 |
| 7309782 |
Crystal forms of azithromycin |
Andrew Trask |
2007-12-18 |
| 7307156 |
Crystal forms of azithromycin |
Andrew Trask, Joseph E. Mertz |
2007-12-11 |
| 7282486 |
Crystal forms of azithromycin |
Andrew Trask |
2007-10-16 |
| 7144915 |
Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) |
Stephen R. Byrn, David Coates, Karen S. Gushurst, Joseph Francis Krzyzaniak, Henry Morrison +2 more |
2006-12-05 |
| 7105179 |
Crystal forms of azithromycin |
Andrew Trask |
2006-09-12 |
| 7081525 |
Crystal forms of azithromycin |
Andrew Trask |
2006-07-25 |
| 7053192 |
Crystal forms of azithromycin |
Andrew Trask |
2006-05-30 |
| 6977243 |
Crystal forms of azithromycin |
Andrew Trask |
2005-12-20 |
| 6965027 |
Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mark E. Flanagan |
2005-11-15 |
| 6949652 |
Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine |
Ming Kang, Zhengong Bryan Li, Yong Tao |
2005-09-27 |
| 6861413 |
Stable non-dihydrate azithromycin oral suspensions |
Andrew Trask |
2005-03-01 |
| 6844349 |
Salt forms of E-2-methoxy-N-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
John Charles Kath, Daniel Tyler Richter, Andrew Trask |
2005-01-18 |
| 6734308 |
Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3,- dihydroxybutanedioate salts and method of production |
Joseph P. Lyssikatos, Derek Tickner, Linda Newton, Clifford N. Meltz |
2004-05-11 |
| 6683106 |
N-(indole-2-carbonyl)-b-alaninamide crystal forms |
Douglas J. M. Allen, Frank R. Busch, Joseph Francis Krzyzaniak, Susan Orrill, Peter R. Rose +2 more |
2004-01-27 |
| 6645982 |
Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production |
Joseph P. Lyssikatos, Derek Tickner, Linda Newton, Clifford N. Meltz |
2003-11-11 |
| 6605729 |
Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-&bgr;,&dgr;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) |
Stephen R. Byrn, David Coates, Karen S. Gushurst, Joseph Francis Krzyzaniak, Henry Morrison +2 more |
2003-08-12 |
| 6486168 |
Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
Raymond D. Skwierczynski, Kenneth R. Phares, Richard L. Miller, Michael J. Jozwiakowski, Terri F. Busch |
2002-11-26 |
| 6245776 |
Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
Raymond D. Skwierczynski, Kenneth R. Phares, Richard L. Miller, Michael J. Jozwiakowski, Terri F. Busch |
2001-06-12 |
